These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 10612505)
1. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected]. Carlsson AM; Chauhan BC; Lee AA; Leblanc RP Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505 [TBL] [Abstract][Full Text] [Related]
2. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543 [TBL] [Abstract][Full Text] [Related]
3. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835 [TBL] [Abstract][Full Text] [Related]
4. Effect of brimonidine tartrate on ocular hemodynamic measurements. Lachkar Y; Migdal C; Dhanjil S Arch Ophthalmol; 1998 Dec; 116(12):1591-4. PubMed ID: 9869786 [TBL] [Abstract][Full Text] [Related]
5. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. Katz LJ J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359 [TBL] [Abstract][Full Text] [Related]
6. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823 [TBL] [Abstract][Full Text] [Related]
7. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229 [TBL] [Abstract][Full Text] [Related]
8. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Javitt JC; Schiffman RM J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373 [TBL] [Abstract][Full Text] [Related]
9. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466 [TBL] [Abstract][Full Text] [Related]
10. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Katz LJ Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939 [TBL] [Abstract][Full Text] [Related]
12. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R; J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288 [TBL] [Abstract][Full Text] [Related]
14. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Melamed S; David R Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394 [TBL] [Abstract][Full Text] [Related]
15. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Toris CB; Camras CB; Yablonski ME Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. Javitt J; Goldberg I J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742 [TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma. Simsek T; Yanik B; Conkbayir I; Zilelioglu O J Ocul Pharmacol Ther; 2006 Apr; 22(2):79-85. PubMed ID: 16722793 [TBL] [Abstract][Full Text] [Related]
18. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302 [TBL] [Abstract][Full Text] [Related]
19. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting. Weigert G; Resch H; Garhofer G; Fuchsjäger-Mayrl G; Schmetterer L Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4220-5. PubMed ID: 17724210 [TBL] [Abstract][Full Text] [Related]
20. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]